United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

United Therapeutics could eventually use the genetically edited swine to grow organs for human transplant recipients. A public biotechnology company is planning a large project in northeast ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

United Therapeutics Corporation (Nasdaq ... the timing and enrollment of our planned UKidney clinical trial; our plans to seek FDA approval of the UKidney following completion of the clinical ...

The company plans to submit a Biologics ... affect investor confidence. Outlook Therapeutics is still in the investigational stage for its product in the United States, suggesting uncertainty ...

The company plans to submit ... post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical ...

RESEARCH TRIANGLE PARK, N.C. - United Therapeutics (NASDAQ:UTHR ... The company is preparing an investigational new drug application for the UKidney, with plans to initiate a clinical study in 2025, ...

RESEARCH TRIANGLE PARK, N.C. - United Therapeutics (NASDAQ ... an investigational new drug application for the UKidney, with plans to initiate a clinical study in 2025, pending FDA clearance.

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...